JP2017507150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507150A5 JP2017507150A5 JP2016555457A JP2016555457A JP2017507150A5 JP 2017507150 A5 JP2017507150 A5 JP 2017507150A5 JP 2016555457 A JP2016555457 A JP 2016555457A JP 2016555457 A JP2016555457 A JP 2016555457A JP 2017507150 A5 JP2017507150 A5 JP 2017507150A5
- Authority
- JP
- Japan
- Prior art keywords
- sdc
- trap
- daltons
- moiety
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims 14
- 239000012636 effector Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 2
- 229950007866 tanespimycin Drugs 0.000 claims 2
- 239000004066 vascular targeting agent Substances 0.000 claims 2
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930195248 Macbecin Natural products 0.000 claims 1
- PLTGBUPHJAKFMA-UHFFFAOYSA-N Macbecin I Natural products N1C(=O)C(C)=CC=CC(C)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-UHFFFAOYSA-N 0.000 claims 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims 1
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 1
- PLTGBUPHJAKFMA-BMJWZTMLSA-N [(2r,3s,5s,6r,7s,8e,10r,11s,12z,14e)-2,5,6-trimethoxy-3,7,9,11,15-pentamethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](C)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-BMJWZTMLSA-N 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 230000009056 active transport Effects 0.000 claims 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
- 229950010817 alvocidib Drugs 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229950004161 ganetespib Drugs 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 claims 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 claims 1
- 229930192524 radicicol Natural products 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947108P | 2014-03-03 | 2014-03-03 | |
| US61/947,108 | 2014-03-03 | ||
| PCT/US2015/018442 WO2015134464A2 (en) | 2014-03-03 | 2015-03-03 | Targeted therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151197A Division JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017507150A JP2017507150A (ja) | 2017-03-16 |
| JP2017507150A5 true JP2017507150A5 (enExample) | 2018-04-12 |
| JP6576942B2 JP6576942B2 (ja) | 2019-09-18 |
| JP6576942B6 JP6576942B6 (ja) | 2019-11-27 |
Family
ID=54055980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555457A Expired - Fee Related JP6576942B6 (ja) | 2014-03-03 | 2015-03-03 | 標的治療薬 |
| JP2019151197A Pending JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151197A Pending JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10232049B2 (enExample) |
| EP (1) | EP3129064B1 (enExample) |
| JP (2) | JP6576942B6 (enExample) |
| KR (1) | KR20160126078A (enExample) |
| CN (1) | CN106456795A (enExample) |
| AU (1) | AU2015224576A1 (enExample) |
| CA (1) | CA2941618A1 (enExample) |
| IL (1) | IL247624A0 (enExample) |
| MA (1) | MA39481A (enExample) |
| WO (1) | WO2015134464A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| HUE061847T2 (hu) | 2016-10-11 | 2023-08-28 | Arvinas Operations Inc | Androgén receptor célzott degradálására alkalmas vegyületek és eljárások |
| WO2018236796A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Combination therapies comprising targeted therapeutics |
| AU2018289349A1 (en) * | 2017-06-20 | 2020-01-02 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| KR20200016875A (ko) * | 2017-06-20 | 2020-02-17 | 마드리갈 파마슈티칼스 인코포레이티드 | 표적화 치료제 |
| CN109512821B (zh) * | 2017-09-18 | 2021-06-08 | 无锡富泽药业有限公司 | 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用 |
| US20210000966A1 (en) * | 2017-12-14 | 2021-01-07 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| EA202092436A1 (ru) | 2018-05-14 | 2021-05-04 | Нувейшн Био Инк. | Противораковые соединения, нацеливающие на ядерные гормональные рецепторы |
| CA3100216A1 (en) * | 2018-06-01 | 2019-12-05 | Tarveda Therapeutics, Inc. | Combination therapy |
| CN109575044A (zh) * | 2018-12-21 | 2019-04-05 | 西安交通大学 | 2-（喜树碱-10-氧基）乙酰胺类化合物和应用 |
| CN114026106B (zh) | 2019-03-06 | 2025-01-21 | 普洛拉治疗公司 | 阿比特龙前药 |
| US20220175722A1 (en) * | 2019-04-10 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (fgfr2) |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN110003181B (zh) * | 2019-05-22 | 2020-08-28 | 北京凯恩梅格医药科技有限公司 | 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用 |
| EP4126833A1 (en) * | 2020-03-23 | 2023-02-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections |
| CN111499623B (zh) * | 2020-04-01 | 2022-07-08 | 南京缘聚医药科技有限公司 | 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途 |
| AU2021273458A1 (en) | 2020-05-09 | 2022-12-01 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
| EP4291159A1 (en) | 2021-02-15 | 2023-12-20 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| CN114933584B (zh) * | 2021-08-09 | 2022-12-27 | 上海贵之言医药科技有限公司 | 一种二氢-2h-异吲哚酯类化合物 |
| CN116354933B (zh) * | 2021-12-27 | 2025-06-20 | 青岛普泰科生物医药科技有限公司 | 作为雄激素受体调节剂的杂环化合物及其应用 |
| CN115650975B (zh) * | 2022-08-23 | 2024-07-02 | 四川大学华西医院 | 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用 |
| WO2024197429A1 (zh) * | 2023-03-24 | 2024-10-03 | 青岛普泰科生物医药科技有限公司 | 作为雄激素受体调节剂的杂环化合物及其应用 |
| WO2024199473A1 (en) * | 2023-03-31 | 2024-10-03 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025199665A1 (en) * | 2024-03-23 | 2025-10-02 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2330611A1 (en) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| EP1169319A4 (en) | 1999-04-09 | 2005-02-09 | Sloan Kettering Institutefor C | METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY |
| EP1337275A4 (en) | 2000-11-02 | 2007-05-09 | Sloan Kettering Inst Cancer | METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| JP2005520795A (ja) | 2001-12-12 | 2005-07-14 | コンフォーマ・セラピューティクス・コーポレイション | Ｈｓｐ９０阻害活性を有するプリン類似体 |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
| US7769423B2 (en) | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
| CA2549463A1 (en) | 2002-12-12 | 2004-07-01 | Conforma Therapeutics Corporation | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands |
| EP1737825A1 (en) | 2004-03-26 | 2007-01-03 | Van Andel Research Institute | Geldanamycin and derivatives inhibit cancer invasion and identify novel targets |
| PT1817295E (pt) | 2004-11-18 | 2013-02-18 | Synta Pharmaceuticals Corp | Compostos de triazol que modulam a actividade da hsp90 |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2007053792A2 (en) | 2005-11-05 | 2007-05-10 | Amplyx Pharmaceuticals, Inc. | Improving the pharmacokinetics of protease inhibitors and other drugs |
| US8293726B2 (en) | 2005-12-02 | 2012-10-23 | Vianova Labs, Inc. | Treatment of cancer and other diseases |
| GB0526615D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| TWI490212B (zh) | 2006-05-25 | 2015-07-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性之三唑化合物 |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| WO2008108386A1 (ja) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| US20100203114A1 (en) * | 2007-07-09 | 2010-08-12 | Warf - Wisconsin Alumni Research Foundation | Micelle encapsulation of therapeutic agents |
| EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
| WO2010028389A1 (en) | 2008-09-08 | 2010-03-11 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
| WO2011116181A1 (en) | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| JP5675619B2 (ja) | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| US20110217241A1 (en) | 2008-11-14 | 2011-09-08 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging |
| CA2769619C (en) * | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| US20110268722A1 (en) | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
| RU2013122898A (ru) | 2010-10-22 | 2014-11-27 | Университы До Страсбур | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью |
| WO2012096919A1 (en) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| GB201106814D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| JP2014532184A (ja) * | 2011-10-12 | 2014-12-04 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 多重化キナーゼ阻害剤ビーズ及びその使用 |
| US20150184246A1 (en) * | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CA2865021C (en) * | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| AU2014318826B2 (en) | 2013-09-10 | 2019-10-10 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| CA2926586C (en) | 2013-10-11 | 2020-04-07 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
| CA2934030A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| JP6727127B2 (ja) | 2013-12-20 | 2020-07-29 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 |
| WO2015116774A1 (en) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
-
2015
- 2015-03-03 AU AU2015224576A patent/AU2015224576A1/en not_active Abandoned
- 2015-03-03 KR KR1020167027259A patent/KR20160126078A/ko not_active Withdrawn
- 2015-03-03 WO PCT/US2015/018442 patent/WO2015134464A2/en not_active Ceased
- 2015-03-03 MA MA039481A patent/MA39481A/fr unknown
- 2015-03-03 CN CN201580022696.0A patent/CN106456795A/zh active Pending
- 2015-03-03 CA CA2941618A patent/CA2941618A1/en not_active Abandoned
- 2015-03-03 EP EP15758717.1A patent/EP3129064B1/en active Active
- 2015-03-03 JP JP2016555457A patent/JP6576942B6/ja not_active Expired - Fee Related
-
2016
- 2016-08-30 US US15/251,255 patent/US10232049B2/en active Active
- 2016-09-04 IL IL247624A patent/IL247624A0/en unknown
-
2018
- 2018-10-25 US US16/170,733 patent/US10675360B2/en not_active Expired - Fee Related
-
2019
- 2019-08-21 JP JP2019151197A patent/JP2019196406A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507150A5 (enExample) | ||
| JP2015512953A5 (enExample) | ||
| JP2017505777A5 (enExample) | ||
| IL293316A (en) | Intentional healing | |
| SA521421855B1 (ar) | مترافقات عقار-جسم مضاد | |
| NL300929I2 (nl) | Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl | |
| WO2018098269A2 (en) | Peptide-containing linkers for antibody-drug conjugates | |
| EP2708256A3 (en) | Device and method for delivery of a medicament | |
| WO2017059224A3 (en) | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers | |
| ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
| WO2009027644A3 (en) | Compositions for the treatment of neoplastic diseases | |
| WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| AU2012395673A8 (en) | Rapamycin analogs and methods for making same | |
| NZ597051A (en) | Smac mimetic | |
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| RU2014134409A (ru) | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств | |
| WO2007084661A3 (en) | Therapy-enhancing glucan | |
| MX2014014969A (es) | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. | |
| EP1829882A3 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
| JP2010523696A5 (enExample) | ||
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| JP2011505371A5 (enExample) | ||
| JP2019509986A (ja) | トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 | |
| JP2018527360A5 (enExample) |